Sanofi SA (NYSE:SNY) – Equities research analysts at Svb Leerink issued their Q1 2020 earnings estimates for Sanofi in a report issued on Tuesday, February 11th. Svb Leerink analyst G. Porges anticipates that the company will earn $0.81 per share for the quarter. Svb Leerink has a “Market Perform” rating on the stock. Svb Leerink also issued estimates for Sanofi’s Q2 2020 earnings at $0.78 EPS, Q3 2020 earnings at $1.03 EPS, Q4 2020 earnings at $0.82 EPS, FY2023 earnings at $4.31 EPS and FY2024 earnings at $4.61 EPS.
A number of other equities analysts have also recently commented on SNY. Barclays cut shares of Sanofi from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 6th. Leerink Swann started coverage on shares of Sanofi in a report on Tuesday. They issued a “market perform” rating and a $58.00 target price for the company. DZ Bank restated a “neutral” rating on shares of Sanofi in a report on Friday, February 7th. Liberum Capital lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, January 22nd. Finally, Argus restated a “buy” rating and issued a $52.00 target price (up previously from $50.00) on shares of Sanofi in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $52.25.
Institutional investors have recently added to or reduced their stakes in the company. Captrust Financial Advisors bought a new stake in shares of Sanofi in the 4th quarter valued at about $800,000. Orion Portfolio Solutions LLC bought a new stake in shares of Sanofi in the 4th quarter valued at about $107,000. First Republic Investment Management Inc. raised its holdings in shares of Sanofi by 10.7% in the 4th quarter. First Republic Investment Management Inc. now owns 121,980 shares of the company’s stock valued at $6,123,000 after purchasing an additional 11,799 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Sanofi by 28.2% in the 4th quarter. Bank of America Corp DE now owns 7,316,201 shares of the company’s stock valued at $367,274,000 after purchasing an additional 1,607,859 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Sanofi by 156.8% in the 4th quarter. Marshall Wace LLP now owns 390,118 shares of the company’s stock valued at $19,584,000 after purchasing an additional 238,189 shares in the last quarter. Hedge funds and other institutional investors own 7.04% of the company’s stock.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: Inverted Yield Curve
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.